Related Experiment Videos
[How I treat ... sickle cell anemia: current therapies]
1Universitè de Liège, Service d'Hématologie.
Revue Medicale De Liege
|January 5, 2002
Summary
Sickle cell disease complications like vaso-occlusive crisis can be managed with hydration and pain relief. Treatments like hydroxyurea and stem cell transplants offer significant benefits, with new agents under evaluation.
Area of Science:
- Hematology
- Vascular Biology
- Pharmacology
Context:
- Sickle cell disease (SCD) is a genetic blood disorder characterized by frequent complications.
- Vaso-occlusive crisis (VOC), thromboembolic events, and acute chest syndrome (ACS) are common and severe manifestations in SCD patients.
Purpose:
- To outline current and emerging management strategies for sickle cell disease complications.
- To highlight the therapeutic benefits of hydroxyurea and allogeneic stem cell transplantation.
- To introduce novel therapeutic agents targeting VOC and intracellular dehydration.
Summary:
- Management of VOC involves aggressive analgesia and hydration. Anticoagulation and antiplatelet therapy may be used for thromboembolic events.
- Hydroxyurea increases fetal hemoglobin, reducing VOC, transfusions, and ACS. Familial allogeneic stem cell transplantation offers a definitive cure.
- Emerging treatments include nitric oxide (NO) and arginine for severe crises, and magnesium and clotrimazole to prevent erythrocyte dehydration by blocking cation channels.
Impact:
- Improved patient outcomes through optimized management of acute and chronic SCD complications.
- Reduced frequency and severity of painful crises and other life-threatening events.
- Advancement of therapeutic options for sickle cell disease, moving towards more effective and potentially curative treatments.